← Back to Search

Behavioral Intervention

Contingency Management for Methamphetamine Use in HIV/AIDS (EXPRESS+ Trial)

N/A
Recruiting
Led By Michael J Li, PhD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up once every 4 weeks over 12 weeks (i.e., baseline, week 4, week 8, week 12)
Awards & highlights
No Placebo-Only Group

Summary

This trial looks at how changes in inflammation and a type of IFN expression coincide with changes in meth use and viral load in HIV-positive transgender men over 12 weeks.

Who is the study for?
This trial is for HIV-positive males aged 18-45 who have sex with men and are seeking treatment for methamphetamine use disorder. Participants must be on antiretroviral therapy, test positive for meth within 30 days before screening, and can attend bi-weekly appointments. Those using opioids, cocaine, MDMA or identifying as female cannot join.
What is being tested?
The EXPRESS+ study examines if changes in stress markers align with shifts in meth use and viral load over a period of 12 weeks among HIV-positive individuals assigned male at birth who do or don't have a methamphetamine use disorder.
What are the potential side effects?
Since this is a behavioral trial focusing on Contingency Management (a motivational incentive approach), it does not involve medication; therefore, typical drug side effects are not expected. However, participants may experience psychological effects due to the nature of the intervention.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~once every 4 weeks over 12 weeks (i.e., baseline, week 4, week 8, week 12)
This trial's timeline: 3 weeks for screening, Varies for treatment, and once every 4 weeks over 12 weeks (i.e., baseline, week 4, week 8, week 12) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Inflammatory and Type I IFN Gene Expression over 12 weeks
Methamphetamine
Secondary study objectives
Body Weight Changes

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Contingency Management for Methamphetamine ReductionExperimental Treatment1 Intervention
8 weeks of contingency management, twice weekly visits, with escalating rewards from $10 to $40 for negative urine tests
Group II: Non-substance-using ControlActive Control1 Intervention
Observational visits (no intervention) at baseline, Week 4, Week 8, and Week 12 for those who do not use methamphetamine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Contingency Management
2014
Completed Phase 4
~3440

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,562 Previous Clinical Trials
10,262,306 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,582 Previous Clinical Trials
3,326,985 Total Patients Enrolled
Michael J Li, PhDPrincipal InvestigatorUCLA Department of Family Medicine

Media Library

Contingency Management (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05558345 — N/A
Drug Addiction Research Study Groups: Contingency Management for Methamphetamine Reduction, Non-substance-using Control
Drug Addiction Clinical Trial 2023: Contingency Management Highlights & Side Effects. Trial Name: NCT05558345 — N/A
Contingency Management (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05558345 — N/A
~7 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top